Preventive Vaccines Global Market Report 2025

The preventive vaccines market size has grown strongly in recent years. It will grow from $75.94 billion in 2024 to $81.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The historical growth of the market was driven by increased government support, heightened awareness of infectious diseases, expansion of global immunization campaigns, continuous progress in vaccine technologies, and a growing focus on childhood immunizations.

The preventive vaccines market size is expected to see strong growth in the next few years. It will grow to $106.47 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. Contributing factors to this projected growth include a surge in funding for vaccine research, a rising burden of infectious diseases, an uptick in demand for customized vaccines, expanded governmental backing, and wider adoption of cutting-edge vaccine technologies. Key trends anticipated during the forecast period include the evolution of mRNA-based vaccine platforms, the development of next-generation delivery systems, breakthroughs in nanoparticle vaccine formulations, the use of artificial intelligence in vaccine development, and improvements in temperature-controlled vaccine logistics.

The growing prevalence of infectious diseases is expected to drive the expansion of the preventive vaccines market. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can spread through person-to-person contact or environmental exposure. Factors such as increasing urbanization, global travel, and antimicrobial resistance contribute to the accelerated spread and increased difficulty in managing these diseases. Preventive vaccines play a critical role in controlling infectious diseases by stimulating the immune system to recognize and fight off pathogens before infection occurs, ultimately reducing disease incidence and transmission. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that in 2022, infectious diseases were responsible for over 15,770 deaths in the country, with lower respiratory infections accounting for approximately one-third of these non-notifiable disease deaths. Consequently, the rising burden of infectious diseases is fueling the growth of the preventive vaccines market.

Companies in the preventive vaccines market are increasingly focusing on technological advancements, including cutting-edge mRNA technology platforms, to enhance vaccine efficacy, improve safety, accelerate development timelines, and ensure broader protection against emerging infectious disease variants. mRNA technology involves the use of messenger RNA to prompt cells to produce specific proteins that trigger targeted immune responses. For instance, in March 2025, Moderna Inc., a biotechnology firm based in the United States, received FDA approval for mNEXSPIKE (mRNA-1283), a new COVID-19 vaccine. This vaccine is authorized for adults aged 65 and older, as well as individuals aged 12-64 who have one or more CDC-defined risk factors. The release of mNEXSPIKE represents a notable advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier iterations. This innovation is anticipated to enhance vaccine accessibility and distribution, especially in underserved and remote regions.

In April 2024, European LifeCare Group, a UK-based vaccination services provider, acquired PreventVaccins B.V. for an undisclosed sum. This acquisition enabled European LifeCare Group to expand its presence in the European vaccination market and strengthen its services by incorporating the expertise and operations of PreventVaccins B.V. Based in the Netherlands, PreventVaccins B.V. is a biotechnology company specializing in the development of preventive vaccines targeting infectious diseases.

Major players in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, and Afrigen Biologics and Vaccines (Pty) Ltd.

North America was the largest region in the preventive vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in preventive vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the preventive vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Preventive vaccines are biological preparations intended to safeguard individuals from infectious diseases by activating the immune system to identify and combat specific pathogens. These vaccines are administered prior to exposure to a disease-causing agent to either prevent infection or lessen its severity. Preventive vaccines serve as a vital component of public health strategies by helping control the transmission of infectious diseases.

The primary categories of preventive vaccines include live or attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit vaccines, conjugate vaccines, DNA vaccines, and recombinant vector vaccines. Live or attenuated vaccines are developed from weakened versions of viruses or bacteria, capable of inducing a strong and long-lasting immune response without causing the actual disease. These vaccines target diseases such as pneumococcal infections, poliovirus, hepatitis, influenza, measles, rubella, and others. They are distributed through various channels including hospitals, clinics, pharmacies, and other medical outlets. The vaccines are formulated for different age groups, including pediatric, adult, and geriatric populations.

The preventive vaccines market research report is one of a series of new reports that provides preventive vaccines market statistics, including the preventive vaccines industry global market size, regional shares, competitors with the preventive vaccines market share, detailed preventive vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the preventive vaccines industry. This preventive vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The preventive vaccines market consists of sales of toxoid vaccines, plant-based vaccines, and combination vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.